Since it was founded in 1983, Fighting Blindness has invested over €15 million in more than 70 research projects. In 1989, researchers in Trinity College Dublin, funded by Fighting Blindness, were the first in the world to identify the Rhodopsin gene, the first gene implicated in the condition retinitis pigmentosa (RP). Since then we have relentlessly pursued solutions to different causes of sight loss. Our work focuses on rare, inherited and age-related retinal degenerative diseases.
Fighting Blindness investigates every realistic avenue of medical research that has a clear potential to result in therapeutic interventions for people living with all forms of sight loss. Over the past number of years, we have broadened our scope from funding genetic research to looking at new and emerging technologies, particularly cell-based technologies and population studies. Basic and translational research remains key to our research strategy through our five pillars of research.
We are indebted to all the hard-working scientists who have dedicated their time, energy and expertise to research into sight loss conditions.